{"id":"NCT02865720","sponsor":"Shire","briefTitle":"Study of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)","officialTitle":"A Phase 3, Open-label, Single-period Study to Evaluate the Safety and Treatment Effect of Intravenous Administration of C1 Inhibitor (Human) for the Prevention of Angioedema Attacks and Treatment of Breakthrough Attacks in Japanese Subjects With Hereditary Angioedema (HAE)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-08","primaryCompletion":"2017-06-23","completion":"2017-06-23","firstPosted":"2016-08-12","resultsPosted":"2018-12-31","lastUpdate":"2021-06-02"},"enrollment":8,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hereditary Angioedema (HAE)"],"interventions":[{"type":"DRUG","name":"CINRYZE 500 U","otherNames":[]},{"type":"DRUG","name":"CINRYZE 1000 U","otherNames":[]}],"arms":[{"label":"Subjects 2 to 5 years of age","type":"EXPERIMENTAL"},{"label":"Subjects 6 years of age and older","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to determine if an investigational treatment is safe and well tolerated when administered by intravenous (IV) infusion in Japanese subjects with HAE.","primaryOutcome":{"measure":"Number of Participants With Treatment-emergent Adverse Events (TEAEs)","timeFrame":"From start of study drug administration up to Week 12","effectByArm":[{"arm":"CINRYZE 1000 U","deltaMin":7,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":10,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":8},"commonTop":["Nasopharyngitis","Arthralgia","Headache","Intervertebral disc disorder","Abdominal pain"]}}